Implantable Device Therapy

Progress in Cardiovascular Diseases

Volumn 50, Issue 6, 2008, Pages 449-474

  Goldenberg, Ilan ^a,b   Moss, Arthur J ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; METOPROLOL; PLACEBO; PROPAFENONE;

ARTICLE; BLOOD PRESSURE MONITORING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CLINICAL EVALUATION; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY VEIN; COST EFFECTIVENESS ANALYSIS; DEATH; DEFIBRILLATOR; DEVICE THERAPY; DISEASE COURSE; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FUNCTION; HIGH RISK POPULATION; HUMAN; IMPLANT; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; PRACTICE GUIDELINE; QRS COMPLEX; QUALITY OF LIFE; RACE DIFFERENCE; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SURVIVAL;

CARDIAC PACING, ARTIFICIAL; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; HEART DISEASES; HEART FAILURE; HISTORY, 20TH CENTURY; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 43349103935     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2007.09.002     Document Type: Article

References (96)

1. State specific mortality from sudden cardiac death-United States, 1999. MMWR CDC Surveill Summ 51 (2002) 123-126
2. de Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I., et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 30 (1997) 1500-1505
3. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e385-e484
4. Beck C., Pritchard W., and Weil H. Ventricular fibrillation of long duration abolished by electric shock. JAMA 135 (1947) 985-986
5. Zoll P., Linenthal A., Gibson W., et al. Termination of ventricular fibrillation in man by externally applied electric countershock. N Engl J Med 254 (1956) 727-732
6. Lown B., Amarasingham R., and Neuman J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA 182 (1962) 548-555
7. Elmquist R., and Senning A. Implantable pacemaker for the heart (1960, 1959), Iliffe & Sons, Ltd., Paris
8. Chardack W.M., Gage A.A., and Greatbatch W. A transistorized, self-contained, implantable pacemaker for the long-term correction of complete heart block. Surgery 48 (1960) 643-654
9. Mirowski M., Reid P.R., Mower M.M., et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 303 (1980) 322-324
10. Mower MM: Method and apparatus for treating hemodynamic dysfunction. Patent issued May 29,1990.
11. Lehmann M.H., Steinman R.T., Schuger C.D., et al. The automatic implantable cardioverter defibrillator as antiarrhythmic treatment modality of choice for survivors of cardiac arrest unrelated to acute myocardial infarction. Am J Cardiol 62 (1988) 803-805
12. Saksena S., Breithardt G., Dorian P., et al. Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. Prog Cardiovasc Dis 38 (1996) 429-444
13. Tchou P.J., Kadri N., Anderson J., et al. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 109 (1988) 529-534
14. The AVID investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 337 (1997) 1576-1583
15. Connolly S.J., Gent M., Roberts R.S., et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 (2000) 1297-1302
16. Kuck K.H., Cappato R., Siebels J., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102 (2000) 748-754
17. Bigger J.T., Fleiss J.L., Kleiger R., et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69 (1984) 250-258
18. Buxton A.E., Marchlinski F.E., Waxman H.L., et al. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 53 (1984) 1275-1279
19. Wilber D.J., Olshansky B., Moran J.F., et al. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 82 (1990) 350-358
20. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
21. Bigger Jr. J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337 (1997) 1569-1575
22. Hohnloser S.H., Kuck K.H., Dorian P., et al., on behalf of the DINAMIT investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
23. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
24. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
25. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
26. Bardy G.H., Lee K.L., Mark D.B., et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
27. Zipes D.P., Roberts D., and for the Pacemaker-Cardioverter-Defibrillator Investigators. Results of the international study of the implantable pacemaker cardioverter-defibrillator: a comparison of epicardial and endocardial lead systems. Circulation 92 (1995) 59-65
28. Kim S.G. Implantable defibrillator therapy: does it really prolong life? How can we prove it?. Am J Cardiol 71 (1993) 1213-1218
29. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies. Eur Heart J 21 (2000) 2071-2078
30. ACC/AHA/NASPE. 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Circulation 106 (2002) 2145-2161
31. Ezekowitz J.A., Armstrong P.W., and McAlister F.A. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 138 (2003) 445-452
32. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 41 (2003) 1573-1582
33. Nanthakumar K., Epstein A.E., Kay G.N., et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 (2004) 2166-2172
34. Bansch D., Antz M., Boczor S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105 (2002) 1453-1458
35. Buxton A.E., Lee K.L., Fisher J.D., et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
36. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 (2003) 1707-1712
37. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
38. Centers for Medicare and Medicaid Services. National coverage analysis: implantable cardioverter defibrillators (#CAG-00157N). Tracking sheet. Available at:. http://www.cms.hbs.gov/Transmittals/Downloads/RIONCD.pdf
39. Buxton A.E., and Moss A.J. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator?. Circulation 111 (2005) 2537-2549
40. Huang D.T., Sesselberg H.W., McNitt S., et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 18 (2007) 833-838
41. Goldenberg I., and Moss A.J. Treatment of arrhythmias and use of implantable cardioverter-defibrillators to improve survival in elderly patients with cardiac disease. Clin Geriatr Med 23 (2007) 205-219
42. Russo A.M., Stamato N.J., Lehmann M.H., et al. Influence of gender on arrhythmia characteristics and outcome in the Multicenter Unsustained Tachycardia Trial. J Cardiovasc Electrophysiol 15 (2004) 993-998
43. Zareba W., Moss A.J., Jackson Hall W., et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol 16 (2005) 1265-1270
44. Henyan N.N., White C.M., Gillespie E.L., et al. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. J Intern Med 260 (2006) 467-473
45. Zareba W., Piotrowicz K., McNitt S., et al. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 95 (2005) 1487-1491
46. Wilber D.J., Zareba W., Hall W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (2004) 1082-1084
47. Goldenberg I., Moss A.J., McNitt S., et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Time-dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial-II. J Am Coll Cardiol 47 (2006) 1811-1817
48. Bax J.J., Visser F.C., Poldermans D., et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 104 (2001) I314-I1318
49. Camici P.G., and Rimoldi O.E. The contribution of hibernation to heart failure. Ann Med 36 (2004) 440-447
50. Goldenberg I., Moss A.J., McNitt S., et al., for the Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 98 (2006) 485-490
51. Goldenberg I., Moss A.J., McNitt S., et al. Inverse relationship of blood pressure levels to sudden cardiac mortality and benefit of the implantable cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 49 (2007) 1427-1433
52. Vorobiof G., Goldenberg I., Moss A.J., et al. Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol 98 (2006) 1383-1386
53. Singh J.P., Hall W.J., McNitt S., et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 46 (2005) 1712-1720
54. Pietrasik G., Goldenberg I., McNitt S., et al. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol 18 (2007) 181-184
55. Goldenberg I., Moss A.J., McNitt S., et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 17 (2006) 931-936
56. Brodine W.N., Tung R.T., Lee J.K., et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 96 (2005) 691-695
57. Vyas A.K., Guo H., Moss A.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
58. Daubert J.P., Zareba W., Hall W.J., et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 47 (2006) 98-107
59. Mushlin A.I., Hall W.J., Zwanziger J., et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97 (1998) 2129-2135
60. Larsen G., Hallstrom A., McAnulty J., et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 105 (2002) 2049-2057
61. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
62. Al-Khatib S.M., Anstrom K.J., Eisenstein E.L., et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 142 (2005) 593-600
63. Zwanziger J., Hall W.J., Dick A.W., et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 2310-2318
64. Goldenberg I, Vyas AK, Hall WJ, et al; for the Multicenter Automatic Defibrillator Implantation Trial-II Investigators; Risk stratification for primary implantation of a cardioverter defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (in press).
65. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123
66. Goldenberg I., Moss A.J., Hall W.J., et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the MADIT-II trial. Circulation 113 (2006) 2810-2817
67. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
68. Linde C., Leclercq C., Rex S., et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40 (2002) 111-118
69. Auricchio A., Stellbrink C., Sack S., et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 39 (2002) 2026
70. Saxon L.A., De Marco T., Schafer J., et al. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 105 (2002) 1304-1310
71. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
72. St John Sutton M.G., Plappert T., Abraham W.T., et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107 (2003) 1985-1990
73. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
74. Cleland J.G., Daubert J.C., Erdmann E., et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 27 (2006) 1928-1932
75. Bax J.J., Abraham T., Barold S.S., et al. Cardiac resynchronization therapy: part 1-issues before device implantation. J Am Coll Cardiol 46 (2005) 2153-2167
76. Jongbloed M.R., Lamb H.J., Bax J.J., et al. Noninvasive visualization of the cardiac venous system using multislice computed tomography. J Am Coll Cardiol 45 (2005) 749-753
77. Bax J.J., Abraham T., Barold S.S., et al. Cardiac resynchronization therapy: part 2-issues during and after device implantation and unresolved questions. J Am Coll Cardiol 46 (2005) 2168-2182
78. Sogaard P., Egeblad H., Pedersen A.K., et al. Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation 106 (2002) 2078-2084
79. Leclercq C., Walker S., Linde C., et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 23 (2002) 1780-1787
80. Gasparini M., Auricchio A., Regoli F., et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 48 (2006) 734-743
81. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost-effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 (2005) 2311-2321
82. Nichol G., Kaul P., Huszti E., et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 141 (2004) 343-351
83. Medtronic Inc. Overview and history of ICD therapy. Available at:. http://www.medtronic.com/physician/tachy/history/Overview_ICD.ppt
84. Pavia S., and Wilkoff B. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Curr Opin Cardiol 16 (2001) 66-71
85. Chen L., and Hay J.W. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther 18 (2004) 161-170
86. Maisel W.H. Safety issues involving medical devices: implications of recent implantable cardioverterdefibrillator malfunctions. JAMA 294 (2005) 955-958
87. Maisel W.H., Moynahan M., Zuckerman B.D., et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 295 (2006) 1901-1906
88. Amin M.S., Matchar D.B., Wood M.A., et al. Management of recalled pacemakers and implantable cardioverter-defibrillators. A decision analysis model. JAMA 296 (2006) 412-420
89. Steinberg J.S., Fischer A., Wang P., et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol 4 (2005) 359-365
90. Vollmann D., Luthje L., Vonhof S., et al. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm 2 (2005) 307-309
91. Klein R.C., Raitt M.H., Wilkoff B.L., et al. Analysis of Implantable Cardioverter Defibrillator Therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 14 (2003) 940-948
92. Wilkoff B.L., Hess M., Young J., et al. Differences in tachyarrhythmia. detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 15 (2004) 1002-1009
93. Daubert JP, Zareba W, Cannom DS. Inappropriate ICD shocks in MADIT II. Frequency, mechanisms, predictors and survival impact. J Am Coll Cardiol (in press).
94. Schron E.B., Exner D.V., Yao Q., et al. Quality of life in the Antiarrhythmics Versus Implantable Defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105 (2002) 589-594
95. Irvine J., Dorian P., Baker B., et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 144 (2002) 282-289
96. Piotrowicz K., Noyes K., Lyness J.M., et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial. Eur Heart J 28 (2007) 601-607